RECRUITING

Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins

Talk to us

Conditions

Rheumatoid Arthritis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study is designed to learn more about the causes of rheumatoid arthritis (RA). People who get RA have elevated protein markers called autoantibodies in their blood years before initial symptoms of arthritis. The goal of this study is to learn more about how autoantibodies in RA might be related to inflammation in the lungs.

Official Title

Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins

Quick Facts

Study Start:2020-08-01
Study Completion:2025-07-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04474392

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults between 18 and 100 years;
  2. * At-Risk for RA, RA diagnosed, and Healthy Control subjects will be included in the study until recruitment goals are met for each group.
  3. 1. No evidence of inflammatory arthritis on clinical examination AND
  4. 2. At elevated risk for RA based on familial or serologic risk
  5. * Familial risk includes having a first degree relatives (FDRs) with RA
  6. * Serologic risk includes asymptomatic serum ACPA positivity
  7. 1. No history of RA
  8. 2. No FDRs with RA
  9. 3. No systemic use of immunosuppressants for autoimmune disease
  10. 1. Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR
  11. 2. Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)
  1. 1. Currently pregnant or planning to become pregnant during the sample collection period of the study
  2. 2. Exacerbation of underlying obstructive lung disease within the past 1 month
  3. 3. Known FEV1 \<1 liter
  4. 4. Oxygen requirement \>2 liters at rest
  5. 5. Participants with health acuity or behavioral health concerns leaving them unable to participate in the current research

Contacts and Locations

Study Contact

Kasey Bales
CONTACT
303-724-0071
KASEY.BALES@CUANSCHUTZ.EDU
Kristin Sturm, MA
CONTACT
303-724-5658
KRISTIN.STURM@CUANSCHUTZ.EDU

Principal Investigator

Kristen Demoruelle, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Colorado, Denver

Study Locations (Sites)

University of Colorado Denver (Anschutz Medical Campus)
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Kristen Demoruelle, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-08-01
Study Completion Date2025-07-14

Study Record Updates

Study Start Date2020-08-01
Study Completion Date2025-07-14

Terms related to this study

Additional Relevant MeSH Terms

  • Rheumatoid Arthritis